Inhibition of lymphocyte mitogenesis by factor(s) released from macrophages isolated from ascitic fluid of advanced ovarian cancer patients
- PMID: 6332671
- PMCID: PMC11039279
- DOI: 10.1007/BF00205484
Inhibition of lymphocyte mitogenesis by factor(s) released from macrophages isolated from ascitic fluid of advanced ovarian cancer patients
Abstract
Ascitic fluid from women with advanced ovarian carcinomas was shown to contain factor(s) which inhibit(s) T lymphocyte mitogenesis. The factor(s) was (were) demonstrated to be associated with the infiltrating macrophages. The inhibition was reversible and inhibited mitogenesis at some late event in the cell cycle. The inhibitory substance(s) was (were) noncytotoxic, dialyzable, heat-stable at 70 degrees C for 10 min (but unstable at 100 degrees C for 15 min), and partially resistant to protease treatment (55%-70%). Further experiments demonstrated that macrophages isolated from the ascitic fluid of patients with cirrhosis of the liver also released factor(s) which inhibit(s) T lymphocyte mitogenesis. On the basis of our data and data from other investigators, we propose that in advanced human ovarian cancer of epithelial origin, macrophages which infiltrate the ascitic fluid elaborate nonspecific inhibitors of T lymphocyte blastogenesis within the proximal environment, resulting in localized immunosuppression and the subsequent enhancement of metastasis within the peritoneal cavity, the tumor cells themselves being resistant to the cytocidal action of the macrophages due to genetic selection and/or their inherent biochemical ability to circumvent normal immunosurveillance mechanisms. This may account, at least in part, for the rapid metastasis and poor prognosis of human ovarian adenocarcinomas.
Similar articles
-
Immunological changes in the ascites of cancer patients after intraperitoneal administration of the bispecific antibody catumaxomab (anti-EpCAM×anti-CD3).Gynecol Oncol. 2015 Aug;138(2):343-51. doi: 10.1016/j.ygyno.2015.06.003. Epub 2015 Jun 3. Gynecol Oncol. 2015. PMID: 26049121 Clinical Trial.
-
New approach to management of malignant ascites with a streptococcal preparation, OK-432. II. Intraperitoneal inflammatory cell-mediated tumor cell destruction.Surgery. 1983 Mar;93(3):365-73. Surgery. 1983. PMID: 6600854
-
Inhibition of human lymphoblastoid cell line proliferation by ascites fluids from ovarian cancer patients.Cancer Res. 1980 Dec;40(12):4495-500. Cancer Res. 1980. PMID: 7438082
-
Tumor cytolysis by lymphocytes infiltrating ovarian malignant ascites.Cancer Res. 1991 Aug 15;51(16):4257-65. Cancer Res. 1991. PMID: 1868446
-
B lymphocyte function in patients with rheumatoid arthritis: impact of regulatory T lymphocytes and macrophages--modulation by antirheumatic drugs.Dan Med Bull. 1988 Apr;35(2):140-57. Dan Med Bull. 1988. PMID: 3282810 Review.
Cited by
-
Gene-modified dendritic cells for immunotherapy against cancer.Med Oncol. 2002;19(4):197-211. doi: 10.1385/MO:19:4:197. Med Oncol. 2002. PMID: 12512913 Review.
-
COVID-19 and cytokine storm syndrome: can what we know about interleukin-6 in ovarian cancer be applied?J Ovarian Res. 2021 Feb 8;14(1):28. doi: 10.1186/s13048-021-00772-6. J Ovarian Res. 2021. PMID: 33550983 Free PMC article. Review.
References
-
- Ablin RJ. Immunobiology of the prostate. In: Tannebaum M, editor. Urologic pathology — The prostate; Vol 1. Philadelphia: Lea and Febiger; 1977. pp. 33–58.
-
- Badger AM, Cooperband SR, Merluzzi VJ, Glasgow AH. Immunosuppressive activity of ascitic fluid from patients with cancer metastatic to the peritoneum. Cancer Res. 1977;37:1200. - PubMed
-
- Boyum A. Separation of white blood cells. Nature. 1954;204:793. - PubMed
-
- Carr I. Macrophages in human cancer. A review. In: James K, McBride B, Stuart A, editors. The macrophage and cancer. Edinburgh: University Press; 1977. pp. 364–374.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical